Common O
increased O
hippocampal O
volume O
but O
specific O
changes O
in O
functional O
connectivity O
in O
schizophrenia O
patients O
in O
remission O
and O
non-remission O
following O
electroconvulsive O
therapy O
: O
A O
preliminary O
study O
Highlights O
Electroconvulsive O
therapy O
( O
ECT O
) O
induced O
enlargement O
in O
hippocampus O
volume O
contrast O
to O
pharmaceutical O
therapy O
in O
schizophrenia O
. O

Both O
ECT O
responders O
and O
non-responders O
show O
hippocampal O
volume O
expansion O
. O

Increased O
FC O
between O
hippocampus O
and O
brain O
cognitive O
networks O
only O
in O
ECT O
responders O
. O

Electroconvulsive O
therapy O
( O
ECT O
) O
is O
considered O
a O
treatment O
option O
in O
patients O
with O
drug-resistant O
schizophrenia O
( O
SZ O
) O
. O

However O
, O
approximately O
one-third O
of O
patients O
do O
not O
benefit O
from O
ECT O
in O
the O
clinic O
. O

Thus O
, O
it O
is O
critical O
to O
investigate O
differences O
between O
ECT O
responders O
and O
non-responders O
. O

Accumulated O
evidence O
has O
indicated O
that O
one O
region O
of O
ECT O
action O
is O
the O
hippocampus O
, O
which O
also O
plays O
an O
important O
role O
in O
SZ O
pathophysiology O
. O

To O
date O
, O
no O
studies O
have O
investigated O
differences O
in O
ECT O
effects O
in O
the O
hippocampus O
between O
treatment O
responders O
and O
non-responders O
. O

This O
study O
recruited O
twenty-one O
SZ O
patients O
treated O
for O
four O
weeks O
with O
ECT O
( O
MSZ O
, O
n O
= O
21 O
) O
and O
twenty-one O
SZ O
patients O
who O
received O
pharmaceutical O
therapy O
( O
DSZ O
, O
n O
= O
21 O
) O
. O

The O
MSZ O
group O
was O
further O
categorized O
into O
responders O
( O
MSR O
, O
n O
= O
10 O
) O
or O
non-responders O
( O
MNR O
, O
n O
= O
11 O
) O
based O
on O
treatment O
outcomes O
by O
the O
criterion O
of O
a O
50 O
% O
reduction O
in O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
total O
scores O
. O

Using O
structural O
and O
resting-state O
functional O
MRI O
, O
we O
measured O
the O
hippocampal O
volume O
and O
functional O
connectivity O
( O
FC O
) O
in O
all O
SZ O
patients O
( O
before O
and O
after O
treatment O
) O
and O
23 O
healthy O
controls O
. O

In O
contrast O
to O
pharmaceutical O
therapy O
, O
ECT O
induced O
bilateral O
hippocampal O
volume O
increases O
in O
the O
MSZ O
. O

Both O
the O
MSR O
and O
MNR O
exhibited O
hippocampal O
expansion O
after O
ECT O
, O
whereas O
a O
lower O
baseline O
volume O
in O
one O
of O
hippocampal O
subfield O
( O
hippocampus-amygdala O
transition O
area O
) O
was O
found O
in O
the O
MNR O
. O

After O
ECT O
, O
increased O
FC O
between O
the O
hippocampus O
and O
brain O
networks O
associated O
with O
cognitive O
function O
was O
only O
observed O
in O
the O
MSR O
. O

The O
mechanism O
of O
action O
of O
ECT O
in O
schizophrenia O
is O
complex O
. O

A O
combination O
of O
baseline O
impairment O
level O
, O
ECT-introduced O
morphological O
changes O
and O
post-ECT O
FC O
increases O
in O
the O
hippocampus O
may O
jointly O
contribute O
to O
the O
post-ECT O
symptom O
improvements O
in O
patients O
with O
SZ O
. O

Materials O
and O
methods O
Participants O
In O
the O
present O
study O
, O
forty-two O
patients O
with O
acute O
SZ O
were O
divided O
into O
two O
groups O
according O
to O
treatment O
strategy O
. O

One O
group O
received O
a O
four-week O
ECT O
series O
in O
addition O
to O
antipsychotic O
drugs O
( O
MSZ O
group O
, O
n O
= O
21 O
) O
; O
the O
other O
group O
received O
only O
antipsychotic O
drugs O
( O
DSZ O
group O
, O
n O
= O
21 O
) O
. O

All O
inpatients O
were O
recruited O
from O
the O
Shanghai O
Mental O
Health O
Centre O
( O
SMHC O
) O
from O
October O
2013 O
to O
January O
2015 O
. O

The O
patients O
were O
diagnosed O
with O
SZ O
by O
trained O
clinical O
psychiatrists O
using O
the O
SCID-I/P O
( O
Structural O
Clinical O
Interview O
for O
DSM-IV-TR O
, O
Patient O
edition O
) O
and O
met O
the O
indications O
for O
ECT O
. O

In O
addition O
, O
the O
patients O
had O
no O
history O
of O
ECT O
within O
the O
previous O
six O
months O
. O

Psychiatric O
symptom O
severity O
was O
assessed O
by O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
, O
and O
the O
total O
PANSS O
scores O
of O
all O
patients O
were O
greater O
than O
60 O
. O

All O
patients O
received O
antipsychotic O
medications O
, O
and O
the O
daily O
antipsychotic O
medication O
dosage O
was O
converted O
to O
chlorpromazine O
equivalents O
( O
mg/d O
) O
. O

Additional O
details O
regarding O
the O
antipsychotic O
medication O
for O
each O
patient O
are O
provided O
in O
Supplementary O
Information O
1 O
. O

A O
sample O
of O
healthy O
controls O
( O
HC O
, O
n O
= O
23 O
) O
, O
which O
was O
matched O
to O
the O
patient O
groups O
by O
age O
, O
sex O
and O
education O
level O
( O
Table O
1 O
) O
, O
was O
also O
recruited O
from O
the O
faculty O
in O
SMHC O
. O

All O
healthy O
controls O
did O
not O
have O
a O
lifetime O
psychiatric O
disorder O
or O
family O
history O
of O
psychosis O
in O
their O
first-degree O
relatives O
. O

Potential O
participants O
were O
excluded O
if O
they O
had O
brain O
injuries O
, O
organic O
mental O
disorders O
, O
neurological O
abnormalities O
, O
other O
serious O
physical O
illnesses O
, O
dementia O
, O
substance O
abuse O
or O
dependence O
, O
or O
contraindications O
to O
MRI O
. O

The O
Ethics O
Committee O
of O
SMHC O
approved O
the O
study O
protocol O
. O

Written O
informed O
consent O
was O
obtained O
from O
all O
subjects O
prior O
to O
study O
participation O
. O

Electroconvulsive O
therapy O
Using O
a O
therapeutic O
apparatus O
Thymatron O
System O
IV O
( O
Somatics O
, O
Lake O
Bluff O
, O
IL O
, O
USA O
) O
, O
ECT O
was O
administered O
3 O
times O
weekly O
for O
4 O
weeks O
and O
12 O
sessions O
. O

Before O
ECT O
, O
succinylcholine O
chloride O
( O
1.0 O
mg/kg O
) O
was O
used O
to O
relax O
muscles O
, O
atropine O
( O
0.5 O
mg O
) O
was O
applied O
to O
reduce O
airway O
secretion O
, O
etomidate O
( O
0.21–0.3 O
mg/kg O
) O
and O
propofol O
( O
1.82–2.44 O
mg/kg O
) O
were O
conducted O
to O
keep O
anaesthesia O
. O

Two O
electrodes O
were O
placed O
at O
bilateral O
temporal O
scalps O
. O

The O
main O
parameters O
of O
ECT O
were O
similar O
for O
all O
patients O
( O
frequency O
, O
10–70 O
Hz O
; O
maximum O
charge O
delivered O
, O
504 O
mC O
; O
output O
current O
, O
0.9 O
A O
; O
pulse O
width O
, O
1.0 O
ms O
; O
maximum O
stimulus O
duration O
, O
8 O
s O
) O
. O

During O
ECT O
, O
we O
monitored O
motor O
convulsions O
and O
induced O
tachycardia O
, O
and O
also O
recorded O
electroencephalogram O
and O
electromyogram O
( O
when O
necessary O
) O
. O

The O
antipsychotic O
therapy O
remained O
stable O
during O
ECT O
period O
except O
for O
the O
discontinuation O
of O
pharmacotherapy O
in O
the O
morning O
before O
ECT O
. O

Symptom O
assessments O
At O
pre- O
and O
post-treatment O
, O
we O
measured O
the O
positive O
( O
PANSS-P O
) O
, O
negative O
( O
PANSS-N O
) O
, O
general O
psychopathology O
( O
PANSS-G O
) O
subscales O
and O
total O
scores O
( O
PANSS-T O
) O
. O

The O
PANSS O
reductive O
ratio O
was O
defined O
as O
percentage O
PANSS O
changes O
as O
: O
△PANSS-T O
% O
= O
( O
PANSS-Tt1−PANSS-Tt2 O
) O
× O
100 O
/ O
( O
PANSS-Tt1−30 O
) O
. O

PANSS-Tt1−30 O
was O
used O
as O
baseline O
value O
instead O
of O
PANSS-Tt1 O
as O
30 O
was O
the O
lowest O
possible O
value O
for O
PANSS O
total O
score O
. O

Similarly O
, O
△PANSS-P O
% O
, O
△PANSS-N O
% O
, O
△PANSS-G O
% O
were O
also O
calculated O
. O

After O
ECT O
, O
the O
MSZ O
group O
was O
further O
classified O
as O
the O
ECT O
responder O
( O
MSR O
group O
, O
n O
= O
10 O
) O
and O
non-responder O
( O
MNR O
group O
, O
n O
= O
11 O
) O
groups O
, O
with O
the O
criterion O
of O
less O
than O
50 O
% O
individual O
symptom O
relief O
for O
non-response O
according O
to O
the O
PANSS O
total O
reductive O
ratio O
. O

Similarly O
, O
the O
DSZ O
group O
was O
also O
grouped O
to O
the O
drug O
responder O
( O
DR O
, O
n O
= O
12 O
) O
and O
non-responder O
groups O
( O
DNR O
, O
n O
= O
9 O
) O
. O

The O
responders O
and O
non-responders O
did O
not O
differ O
in O
terms O
of O
gender O
, O
age O
, O
education O
, O
illness O
duration O
and O
baseline O
PANSS O
scores O
( O
Table O
1 O
) O
. O

Data O
acquisition O
Whole-brain O
imaging O
data O
were O
acquired O
using O
a O
3-T O
Siemens O
Magnetom O
veriosyngo O
MR O
B17 O
scanner O
. O

Functional O
MRI O
data O
were O
obtained O
by O
a O
gradient O
echo O
planar O
imaging O
( O
EPI O
) O
sequence O
( O
TR O
2000 O
ms O
; O
TE O
, O
30 O
ms O
; O
flip O
angle O
, O
90° O
; O
FOV O
, O
220 O
mm O
× O
220 O
mm O
; O
matrix O
, O
64 O
× O
64 O
; O
slice O
thickness O
, O
4 O
mm O
; O
30 O
slices O
; O
voxel O
size O
, O
3.4 O
× O
3.4 O
× O
3.4 O
mm O
; O
180 O
vol O
) O
. O

In O
addition O
, O
high-resolution O
T1-weighted O
structural O
images O
were O
collected O
using O
a O
magnetization-prepared O
rapid O
acquisition O
gradient O
echo O
( O
MPRAGE O
) O
sequence O
( O
TR O
, O
2530 O
ms O
, O
TE O
, O
2.56 O
ms O
, O
flip O
angle O
, O
7° O
, O
inversion O
time O
, O
1100 O
ms O
, O
FOV O
, O
256 O
mm O
× O
256 O
mm O
, O
matrix O
, O
256 O
× O
256 O
, O
224 O
slices O
, O
slice O
thickness O
, O
1 O
mm O
; O
voxel O
size O
, O
1.0 O
× O
1.0 O
× O
1.0 O
mm O
) O
. O

The O
patients O
were O
scanned O
twice O
before O
( O
baseline O
) O
and O
after O
4-week O
therapy O
. O

The O
HC O
underwent O
scanning O
only O
at O
baseline O
. O

The O
first O
MRI O
scan O
of O
patients O
was O
obtained O
within O
24 O
h O
before O
the O
first O
ECT O
, O
and O
the O
final O
MRI O
scan O
was O
collected O
24–48 O
h O
after O
the O
last O
session O
of O
ECT O
. O

Participants O
were O
instructed O
to O
keep O
their O
eyes O
closed O
, O
relax O
, O
but O
not O
to O
fall O
sleep O
. O

Data O
processing O
2.5.1 O
. O

Hippocampal O
structural O
analysis O
A O
longitudinal O
segmentation O
of O
hippocampal O
substructures O
was O
performed O
using O
FreeSurfer O
( O
version O
6.0 O
, O
http O
: O
//surfer.nmr.mgh.harvard.edu/ O
) O
. O

Specifically O
, O
a O
longitudinal O
processing O
stream O
including O
skull O
stripping O
, O
tissue O
segmentation O
, O
surface O
reconstruction O
, O
registration O
and O
parcellation O
, O
was O
applied O
to O
all O
subjects O
' O
T1 O
images O
in O
Freesurfer O
. O

This O
stream O
created O
an O
unbiased O
within-subject O
template O
space O
by O
using O
robust O
, O
inverse O
consistent O
registration O
across O
scanning O
images O
. O

A O
longitudinal O
segmentation O
of O
hippocampal O
subfields O
tool O
in O
Freesurfer O
was O
also O
applied O
to O
segmented O
hippocampal O
regions O
to O
obtain O
twelve O
hippocampal O
subfields O
for O
each O
hemisphere O
. O

The O
longitudinal O
algorithm O
uses O
a O
subject-specific O
atlas O
and O
treats O
all O
scanning O
time O
points O
the O
same O
way O
to O
avoid O
processing O
bias O
, O
and O
thus O
increases O
the O
robustness O
of O
segmentation O
. O

Whole O
hippocampal O
volume O
and O
twelve O
subfields O
volumes O
were O
measured O
for O
each O
hemisphere O
, O
including O
the O
hippocampal O
tail O
, O
subiculum O
, O
presubiculum O
, O
parasubiculum O
, O
cornu O
ammonis O
area O
1 O
( O
CA1 O
) O
, O
CA3 O
, O
CA4 O
, O
hippocampal O
fissure O
, O
granular O
cells O
layer O
of O
the O
dentate O
gyrus O
( O
GC-ML-DG O
) O
, O
molecular O
layer O
, O
hippocampus-amygdala O
transition O
area O
( O
HATA O
) O
and O
fimbria O
. O

Illustrations O
of O
hippocampal O
subfield O
segmentation O
for O
each O
subject O
are O
provided O
in O
Supplementary O
Information O
2 O
. O

2.5.2 O
. O

Hippocampal O
resting-state O
functional O
connectivity O
analysis O
Resting-state O
fMRI O
processing O
was O
performed O
in O
SPM12 O
( O
http O
: O
//www.fil.ion.ucl.ac.uk/spm O
) O
and O
DPABI O
( O
http O
: O
//rfmri.org/dpabi O
) O
software O
. O

The O
fMRI O
data O
preprocessing O
pipeline O
was O
similar O
with O
previous O
study O
and O
was O
only O
briefly O
described O
here O
. O

Firstly O
, O
the O
first O
10 O
time O
points O
were O
removed O
for O
signal O
equilibrium O
and O
to O
allow O
the O
subjects O
’ O
adaptation O
to O
the O
scanning O
noise O
; O
secondly O
, O
we O
did O
the O
slice-timing O
correction O
, O
realignment O
correction O
, O
normalization O
and O
resampling O
to O
3 O
× O
3 O
× O
3 O
mm3 O
; O
thirdly O
, O
the O
nuisance O
covariates O
including O
24 O
motion O
parameters O
, O
white O
matter O
and O
cerebrospinal O
fluid O
signals O
and O
linear O
trending O
were O
regressed O
out O
; O
then O
, O
we O
performed O
temporally O
scrubbing O
and O
temporal O
filtering O
( O
0.01–0.1 O
Hz O
) O
; O
finally O
, O
the O
data O
was O
smoothed O
( O
FWHM= O
6 O
mm O
) O
. O

Following O
the O
preprocessing O
, O
seed-based O
FC O
analysis O
was O
used O
to O
evaluate O
the O
hippocampal O
FC O
. O

Four O
regions O
of O
bilateral O
rostral O
hippocampus O
( O
RosHIP O
) O
and O
caudal O
hippocampus O
( O
CauHIP O
) O
were O
defined O
as O
the O
seed O
ROIs O
according O
to O
the O
Human O
Brainnetome O
Atlas O
. O

Pearson O
's O
correlation O
coefficients O
between O
the O
time O
series O
of O
each O
seed O
and O
that O
of O
the O
other O
voxels O
in O
the O
whole O
brain O
were O
calculated O
and O
then O
Fisher O
's O
z-transformed O
to O
z-scores O
. O

For O
each O
subject O
and O
each O
seed O
, O
a O
FC O
z-score O
map O
was O
obtained O
and O
used O
for O
following O
statistical O
analysis O
. O

2.6 O
. O

Statistical O
analysis O
2.6.1 O
. O

Hippocampal O
volume O
comparisons O
To O
determine O
whether O
the O
hippocampal O
volume O
changes O
were O
a O
specific O
effect O
induced O
by O
ECT O
rather O
than O
drug O
, O
repeated O
measured O
two-way O
ANOVA O
was O
performed O
on O
the O
volumes O
of O
the O
whole O
hippocampus O
and O
each O
subfield O
with O
the O
between-subject O
factor O
( O
treatment O
strategy O
: O
MSZ O
vs. O
DSZ O
) O
and O
the O
within-subject O
factor O
( O
time O
: O
t1 O
vs. O
t2 O
) O
. O

Post-hoc O
paired O
t-tests O
were O
performed O
in O
the O
MSZ O
and O
DSZ O
groups O
to O
indentify O
longitudinal O
changes O
after O
controlling O
for O
the O
overall O
intracranial O
volume O
. O

To O
further O
examine O
whether O
hippocampal O
volume O
changes O
were O
different O
between O
the O
ECT O
responders O
and O
non-responders O
, O
repeated O
measured O
two-way O
ANOVA O
was O
conducted O
with O
the O
between-subject O
factor O
( O
MSR O
vs. O
MNR O
) O
and O
the O
within-subject O
factor O
( O
time O
: O
t1 O
vs. O
t2 O
) O
. O

Two O
post-hoc O
paired O
t-tests O
were O
separately O
performed O
in O
the O
MSR O
and O
MNR O
groups O
to O
characterize O
the O
longitudinal O
changes O
in O
hippocampal O
volume O
after O
the O
ECT O
when O
controlling O
the O
effect O
of O
the O
overall O
intracranial O
volume O
. O

Additionally O
, O
ANOVA O
and O
post-hoc O
tests O
were O
used O
to O
compare O
the O
baseline O
differences O
among O
the O
MSR O
, O
MNR O
and O
HC O
groups O
. O

2.6.2 O
. O

Hippocampal O
FC O
comparisons O
To O
verify O
the O
hypothesis O
that O
ECT O
induced O
specific O
changes O
in O
hippocampal O
FC O
in O
the O
ECT O
responders O
, O
repeated O
measured O
two-way O
ANOVA O
was O
conducted O
with O
the O
between-subject O
factor O
( O
outcome O
: O
MSR O
vs. O
MNR O
) O
and O
the O
within-subject O
factor O
( O
time O
: O
t1 O
vs. O
t2 O
) O
; O
the O
interaction O
effect O
of O
outcome O
and O
time O
was O
used O
to O
investigate O
the O
specific O
changes O
observed O
in O
the O
ECT O
responders O
. O

Two O
post-hoc O
paired O
t-tests O
were O
separately O
performed O
in O
the O
MSR O
and O
MNR O
groups O
to O
detect O
the O
longitudinal O
changes O
in O
hippocampal O
FC O
after O
the O
ECT O
. O

In O
addition O
, O
ANOVA O
and O
post-hoc O
tests O
were O
applied O
to O
the O
comparisons O
amongststststst O
the O
MSR O
, O
MNR O
and O
HC O
groups O
at O
the O
baseline O
. O

For O
these O
analyses O
on O
the O
voxel-wise O
FC O
z-score O
maps O
, O
a O
multiple O
comparison O
correction O
was O
performed O
using O
a O
height O
threshold O
( O
z O
> O
2.7 O
) O
for O
individual O
voxels O
and O
a O
cluster O
size O
based O
on O
the O
Gaussian O
random O
field O
theory O
, O
which O
corresponds O
to O
p O
< O
0.05 O
after O
correction O
. O
. O

Relationship O
between O
hippocampal O
changes O
and O
symptom O
improvements O
The O
hippocampal O
volume O
and O
FC O
values O
that O
exhibited O
significant O
longitudinal O
changes O
were O
extracted O
. O

The O
hippocampal O
volume O
change O
was O
defined O
as O
the O
difference O
in O
volume O
( O
Volumet2 O
- O
Volumet1 O
) O
. O

Similarly O
, O
the O
FC O
changes O
were O
computed O
as O
difference O
values O
( O
FCt2 O
- O
FCt1 O
) O
. O

As O
these O
values O
did O
not O
conform O
to O
a O
normal O
distribution O
according O
to O
the O
Kolmogorov-Smirnov O
tests O
, O
Spearman O
rank O
correlations O
were O
used O
to O
assess O
the O
relationships O
between O
the O
hippocampal O
volume O
or O
FC O
changes O
and O
the O
reductive O
ratios O
of O
the O
symptoms O
( O
△PANSS-P O
% O
, O
△PANSS-N O
% O
, O
△PANSS-G O
% O
, O
and O
△PANSS-T O
% O
) O
in O
the O
MSR O
group O
. O

Power O
analysis O
on O
the O
longitudinal O
changes O
in O
hippocampal O
volume O
and O
FC O
Finally O
, O
to O
estimate O
the O
statistical O
power O
for O
these O
longitudinal O
changes O
in O
hippocampal O
volume O
and O
functional O
connectivity O
in O
the O
MSR O
and O
MNR O
groups O
, O
power O
analyses O
were O
conducted O
using O
the O
G O
* O
Power O
3.1.9.2 O
( O
http O
: O
//www.gpower.hhu.de/ O
) O
. O

Additional O
analysis O
Baseline O
comparisons O
between O
MSZ O
and O
DSZ O
To O
investigate O
the O
differences O
in O
hippocampal O
volume O
and O
FC O
between O
the O
MSZ O
and O
DSZ O
groups O
at O
baseline O
, O
we O
performed O
two-sample O
t-tests O
to O
compare O
the O
differences O
between O
the O
MSZ O
and O
DSZ O
in O
the O
volume O
of O
each O
hippocampal O
subfield O
and O
FC O
. O

Comparisons O
between O
responders O
and O
non-responders O
In O
addition O
, O
we O
divided O
all O
the O
SZ O
patients O
into O
responders O
( O
SZR O
group O
: O
N O
= O
22 O
; O
14 O
female O
; O
30.72±7.38 O
years O
of O
age O
) O
and O
non-responders O
( O
SZNR O
group O
: O
N O
= O
20 O
; O
9 O
female O
; O
29.05±7.24 O
years O
of O
age O
) O
to O
further O
compare O
the O
baseline O
volume O
and O
FC O
across O
groups O
and O
the O
group-by-time O
interactions O
using O
repeated O
measured O
ANOVA O
. O

FC O
changes O
in O
the O
DR O
and O
DNR O
groups O
To O
further O
investigate O
the O
FC O
changes O
due O
to O
pharmacological O
treatment O
, O
paired O
t-tests O
were O
used O
to O
separately O
compare O
the O
differences O
between O
t1 O
and O
t2 O
in O
the O
DR O
and O
DNR O
groups O
. O

